Semax: ACTH-Derived Neuropeptide in Cognitive and Neuroprotection Research

What Is Semax?

Semax is a synthetic heptapeptide (7-amino-acid peptide) derived from the N-terminal region of ACTH(4-10), a fragment of adrenocorticotropic hormone. Its sequence is: Met-Glu-His-Phe-Pro-Gly-Pro

The name "Semax" is a portmanteau of "semaphorin-like" and "ACTH," reflecting its dual parentage. It was developed in the 1980s–1990s at the Institute of Molecular Genetics and the Institute of Bioorganic Chemistry in Moscow, as part of a Soviet-era research program into neuroprotective compounds. It has been used clinically in Russia for cognitive and neuroprotective indications, though regulatory status outside Russia remains limited to research contexts.

Unlike the native ACTH fragment it is derived from, Semax does not stimulate cortisol production or activate the hypothalamic-pituitary-adrenal (HPA) axis in a meaningful way — a property that was specifically engineered into the design by eliminating the HPA-activating segments of the ACTH peptide.

Discovery and Development History

The development of Semax followed from the observation that short fragments of ACTH (particularly the 4-7 fragment, MEHFPGP) could produce behavioral and cognitive effects in animal models without the adrenal stimulation of the full ACTH peptide. Soviet and Russian researchers systematically characterized truncated and modified ACTH sequences to identify which portions carried the cognitive-modulating activity independently of HPA axis effects.

Semax emerged as one of the most pharmacologically active and chemically stable fragments from this screening program. It has been available in Russia as a nasal spray formulation for decades and appears in the Russian pharmacopoeia for acute ischemic stroke and transient ischemic attack indications — though evidence standards for these indications differ from Western regulatory frameworks.

Mechanism of Action

Semax exerts its effects through multiple neurochemical pathways:

BDNF and NGF upregulation

The most consistently replicated finding in Semax research is upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in hippocampal and cortical tissue in animal models. Both BDNF and NGF are critical survival and growth factors for neurons, and their upregulation is associated with synaptic plasticity, neuronal maintenance, and cognitive function in the published literature.

In rodent studies, single-dose Semax administration produces measurable BDNF increases in hippocampal tissue within hours of intranasal delivery. Repeated dosing in animal models produces more sustained elevation.

Dopaminergic and serotonergic system effects

Semax has been shown to modulate neurotransmitter systems in animal models. Published research reports:

Increased dopamine turnover in brain regions associated with motivation and executive function
Effects on serotonin receptor expression and serotonergic transmission
Modulation of enkephalinase activity (enkephalins are endogenous opioid peptides with roles in pain and mood regulation)

VEGF and neuroprotection

In ischemia models, Semax has been associated with upregulation of vascular endothelial growth factor (VEGF) — promoting angiogenesis and collateral circulation in the penumbra region surrounding ischemic tissue. This mechanism is proposed to underlie some of the neuroprotective effects reported in stroke models.

Melanocortin receptor activity

As an ACTH-derived peptide, Semax retains partial affinity for melanocortin receptors (MC4R, MC3R) expressed in the brain. These receptors are implicated in energy regulation, inflammation, and certain aspects of cognitive function. The melanocortin pathway may contribute to some Semax effects, though the primary behavioral effects in published research appear to exceed what melanocortin activation alone would predict.

Research Applications

Cognitive function models

Published preclinical research has examined Semax in spatial learning and memory tasks in rodents — including Morris water maze and passive avoidance tests. Reported effects include:

Faster acquisition of spatial tasks in treated animals compared to controls
Retention improvements in memory consolidation assays
Protection against scopolamine-induced amnesia (a pharmacological model of cholinergic deficit)

These findings have led to Semax's classification as a "cognitive-enhancing" research compound, though the research context is exclusively preclinical.

Neuroprotection in ischemia models

The strongest evidence base for Semax comes from stroke and ischemia research:

Reduction in infarct volume in rodent middle cerebral artery occlusion (MCAO) models
Improved neurological outcomes in post-ischemia behavioral assessments
VEGF upregulation in peri-infarct tissue, with associated angiogenesis
Attenuation of inflammatory cascades (reduced cytokine expression in ischemic tissue)

Published research in this area supports the mechanistic rationale for the Russian clinical indications, though translation to human outcomes requires independent verification.

Pain and stress response

Some published research has examined Semax in models of pain modulation and acute stress, with reported effects on nociceptive thresholds and stress-response behaviors in rodents. These applications are less extensively characterized than the cognitive and ischemia literature.

Handling and Delivery in Research Protocols

Route of administration

Published research typically uses intranasal delivery in animal models, typically via micropipette or specialized rodent nasal cannula. Intranasal delivery bypasses the blood-brain barrier via olfactory nerve pathways and achieves CNS exposure without systemic administration.

Some published protocols use subcutaneous or intraperitoneal injection; this route is less common for Semax but has been used in pharmacokinetic characterization studies.

Half-life considerations

Semax has a short plasma half-life (approximately 7 minutes after intravenous injection in animal models) due to rapid peptidase degradation. The intranasal route is associated with extended CNS tissue presence relative to measured plasma levels, suggesting local olfactory-nerve delivery rather than systemic absorption is the primary route to CNS effect.

Dose forms and reconstitution

Semax is supplied as a lyophilized powder. It is water-soluble and reconstitutes readily at standard research concentrations. Store the lyophilized form at −20 °C and reconstituted solutions at 2–8 °C for short-term use.

See our reconstitution protocol for step-by-step handling.

Semax and Selank: A Common Research Pair

In published nootropic and neuroprotective research, Semax is frequently studied alongside Selank — a synthetic analog of the immune peptide tuftsin. The two peptides have complementary mechanism profiles:

Semax has stronger dopaminergic and activating properties in the published literature; effects are associated with attention, focus, and acute stress response.
Selank has stronger GABAergic and anxiolytic-profile effects in animal models; effects are associated with anxiety and stress modulation.

Some researchers use the two in combination or alternation to study synergistic neuropeptide effects. For detailed mechanism coverage of the companion compound, see our Selank research primer.

Product Availability

Phase 1 Peptides stocks both compounds at 99%+ purity with third-party laboratory documentation:

Semax — research-grade, multiple dose sizes
Selank — research-grade, multiple dose sizes

Summary

Semax is a synthetic heptapeptide derived from ACTH(4-10), developed in Russia for its cognitive and neuroprotective properties in preclinical models. Its primary characterized mechanisms include BDNF/NGF upregulation, dopaminergic modulation, and VEGF-mediated neuroprotection in ischemia models. It is typically delivered intranasally in animal protocols and has a short plasma half-life, relying on olfactory-pathway CNS delivery. Its strongest research application is in stroke and ischemia models; cognitive function research is extensive but primarily preclinical. It is often studied alongside Selank for complementary neuropeptide pathway coverage. For a three-way comparison of Semax, Selank, and DSIP as neuropeptide research tools, see the Neuropeptide Research overview.

How does Semax differ pharmacologically from the ACTH peptide it derives from?

Semax is derived from the ACTH(4-10) fragment but was specifically engineered to eliminate the segments of ACTH responsible for hypothalamic-pituitary-adrenal (HPA) axis activation and cortisol stimulation. In animal models, Semax does not produce the adrenal stimulation that full ACTH causes, while retaining the behavioral and cognitive effects attributed to the shorter ACTH fragment. This separation of cognitive activity from HPA activation was the primary design goal.

What is the primary proposed mechanism for Semax's effects in cognitive research models?

The most consistently replicated finding across published Semax research is upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in hippocampal and cortical tissue in animal models. Both neurotrophins are critical for neuronal survival, synaptic plasticity, and cognitive function. Single-dose intranasal Semax administration in rodent studies produces measurable BDNF increases within hours of delivery.

Why is intranasal delivery used for Semax in published research protocols?

Semax has a short plasma half-life — approximately 7 minutes after intravenous injection in animal models — due to rapid peptidase degradation in systemic circulation. Intranasal delivery bypasses the blood-brain barrier directly via olfactory nerve pathways, achieving CNS tissue concentrations that exceed what systemic plasma levels would predict. This delivery-route advantage makes intranasal administration the standard for published Semax behavioral and neuroprotection studies.

How does Semax compare to Selank as a neuropeptide research tool?

Semax and Selank have complementary rather than overlapping profiles. Semax is characterized by dopaminergic modulation and activating effects, with stronger BDNF elevation and primary research applications in ischemia and cognitive models. Selank acts primarily through GABA-A receptor modulation with anxiolytic-profile effects, with weaker BDNF effects and primary research applications in stress and anxiety-behavior models. The two are frequently studied together or in alternation to obtain broader neuropeptide pathway coverage.